In order to focus on pharmaceutical development, Standard Group has focused on group specialization.With the expectation of pharmaceutical development, Standard has assigned product lines to its subsidiaries, which means each subsidiary can focus on one professional field for profit maximization. Currently, Standard focuses on pharmaceuticals; Syn-tech specializes in API; Syngen covers biotechnology API, health supplements, and medical equipment; Multipower is responsible for the sales of Neoangelac Plus milk powder and adult supplements.
Standard group's business development is based on preventive medicine, medical care, and health industry. At present, Standard is a Listed Company, Syn-Tech trades as an OTC company, and Syngen is an Emerging Company. In order to strengthen Standard group’s business profit, Standard reinvested in YourChance drug store chain and made it become Taiwan’s third-largest direct sales chain system. Standard group works as a team, shares resources, implements vertical integration and horizontal expansion to fully use the function of the organization to become a complete and comprehensive health industry.

Standard has utilized the corporate advantages to implement international distributes for decades. In addition to concentrating on developing niche and specialty generic pharmaceuticals, Standard Group also has upstream and downstream suppliers and promotes GMP production management as well as a global marketing strategy.

Standard Group has though factory expansions in pharmaceuticals, API, food, and patches continuously developed high quality medical and health products. With the corporate mindset of “Taiwanese roots, Global network,” Standard executes multiple business strategies in Taiwan and aboard. In Taiwan, Standard employs hundreds of people to operate direct sales with pharmacies, clinics, hospitals, medical centers, and etc.
For international markets, including Jiangsu Taizhou, Shanghai, the Philippines, the U.S., Vietnam, Thailand, and Canada, Standard has established local subsidiaries or offices and appointed Taiwanese staff or hired local employees for customer services, market strategy, and advertising of our products.

Currently, Standard Group is the leading exporter of the Taiwanese pharmaceutical industry to ASEAN countries. Considering the regulatory barriers to the pharmaceutical industry, any pharmaceutical company has to complete identification and registration of a license before entering a foreign market. As such, it takes years of planning for a company to internationalize. Standard now holds more than a hundred and fifty licenses in ASEAN, China, and the U.S. Standard plans to continue applying for drug licenses in these markets. In the future, Standard Group expects its export value to increase from 20% to 50% of the total profit contribution, and shift from its domestic pharmaceutical industry market into an into an export-based pharmaceutical group.